Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: Screening allows for earlier diagnosis: ORIGINAL ARTICLE

Internal Medicine Journal

Volumn 39, Issue 10, 2009, Pages 682-691

  Phung, S ^a   Strange, G ^b   Chung, L P ^a   Leong, J ^a   Dalton, B ^c   Roddy, J ^a   Deague, J ^d   Playford, D ^d   Musk, M ^a   Gabbay, E ^a,e,f  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Lung Institute of Western Australia   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cardiopulmonary haemodynamics; Prevalence; Pulmonary arterial hypertension; Scleroderma; Systemic sclerosis

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; BRONCHIECTASIS; CLINICAL ASSESSMENT; EARLY DIAGNOSIS; ECHOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCLERODERMA; SCREENING; WALKING;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; WESTERN AUSTRALIA;

EID: 70350110402     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01823.x     Document Type: Article

References (47)

1. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg 1998 17 : 48 54.
2. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004 3 : 339 352.
3. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005 52 : 2125 2132.
4. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994 37 : 1283 1289.
5. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990 113 : 352 357.
6. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004 63 : 1009 1014.
7. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001 40 : 453 459.
8. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996 35 : 989 993.
9. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003 48 : 516 522. (Pubitemid 36278021)
10. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003 123 : 344 350.
11. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006 2 : 134 144.
12. Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007 26 : 181 187.
13. D'Alonzo GE, Barst RJ, Ayres SM, Bergotsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991 115 : 343 349.
14. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003 29 : 335 349, vii.
15. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006 92 : 926 932.
16. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al. Treatment of patients with mildly symptomatic pulmonary hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008 371 : 2093 2100.
17. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 351 : 1425 1436.
18. Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest 1998 114 (3 Suppl 237S 41S.
19. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007 37 : 485 494.
20. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 62 : 1088 1093.
21. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005 52 : 3792 3800.
22. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005 32 : 1273 1278.
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980 23 : 581 590.
24. Miller MR, Crapo R, Hankinson J, van der Grinten CP, Gustafsson P, Jensen R et al. General considerations for lung function testing. Eur Respir J 2005 26 : 153 161.
25. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985 132 : 919 923.
26. Lang R, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards committee and Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005 18 : 1440 1463.
27. Hatle L, Angelsen BA, Tromsdal A. Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. Br Heart J 1981 45 : 157 165.
28. Rich S. Primary Pulmonary Hypertension: Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France; Geneva : The World Health Organization 1998.
29. Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med J Aust 2003 178 : 564 567.
30. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004 25 : 2243 2278.
31. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002 29 : 298 304.
32. Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005 35 : 28 33.
33. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr., Bein M et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983 75 : 65 74.
34. Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996 110 : 1515 1519.
35. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003 124 : 2098 2104.
36. Celermajer DS, Marwick T. Echocardiographic and right heart catheterization techniques in patients with pulmonary arterial hypertension. Int J Cardiol 2008 125 : 294 303.
37. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 126 (1 Suppl 14S 34S. (Pubitemid 38932340)
38. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004 43 : 461 466.
39. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007 116 : 637 647.
40. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003 92 : 1434 1438.
41. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000 102 : 1788 1794.
42. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987 107 : 216 223. (Pubitemid 17137857)
43. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003 361 : 1533 1544.
44. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006 65 : 1336 1340.
45. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006 33 : 269 274.
46. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003 30 : 2398 2405.
47. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997 156 (2 Pt 1 528 535.